Get the Stockscreener App
2.26
1.80%
0.04
After Hours:
2.26
Adc Therapeutics Sa stock is traded at $2.26, with a volume of 307.99K.
It is up +1.80% in the last 24 hours and down -23.39% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
See More
Previous Close:
$2.22
Open:
$2.24
24h Volume:
307.99K
Relative Volume:
0.82
Market Cap:
$219.97M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-0.9956
EPS:
-2.27
Net Cash Flow:
$-121.90M
1W Performance:
+14.14%
1M Performance:
-23.39%
6M Performance:
-38.59%
1Y Performance:
+212.37%
1-Day Range:
$2.21
$2.32
1-Week Range:
$1.86
$2.38
52-Week Range:
$0.6883
$6.04
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
2.26 | 219.97M | 69.56M | -240.05M | -121.90M | -2.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Antibody Drug Conjugate Market Industry Trends and Forecasts to 2035, Featuring Profiles of Key Players ADC Therapeutics, Byondis, Daiichi Sankyo, Genentech, Gilead Sciences, ImmunoGen, RemeGen and More - Yahoo Finance
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Fin - GuruFocus.com
ADC Therapeutics Announces Investigator-Initiated Study Abstract - GuruFocus.com
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates - MSN
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 9.7% - MarketBeat
Head to Head Comparison: ADC Therapeutics (NYSE:ADCT) & Astellas Pharma (OTCMKTS:ALPMY) - Defense World
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Redmile Group, LLC Reduces Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics shareholders approve capital increase - Investing.com India
ADC Therapeutics shareholders approve capital increase By Investing.com - Investing.com UK
Prosight Management, LP Expands Stake in ADC Therapeutics SA - GuruFocus.com
ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript - Insider Monkey
ADC Therapeutics : Guggenheim Healthcare Innovation Conference - Marketscreener.com
Analysts Set ADC Therapeutics SA (NYSE:ADCT) PT at $8.25 - Defense World
ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% UpsideHere's Why - AOL
ADC Therapeutics SA (NYSE:ADCT) Receives $8.25 Average Price Target from Analysts - MarketBeat
ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Marketscreener.com
ADC Therapeutics (NYSE:ADCT) Now Covered by Analysts at Stephens - MarketBeat
ADC Therapeutics SA (ADCT) Quarterly 10-Q Report - Quartzy
ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
ADC Therapeutics SA Reports Q3 2024: EPS of -$0.42 Misses Estima - GuruFocus.com
What To Expect From ADC Therapeutics SA (ADCT) Q3 2024 Earnings - GuruFocus.com
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting - The Malaysian Reserve
ADC Therapeutics' ZYNLONTA Shows 97% Response Rate in Lymphoma Clinical Trials | ADCT Stock News - StockTitan
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - MSN
ADC Therapeutics to Present at November 2024 Investor Conferences - BioSpace
ADC Therapeutics to Present at November Investor Conferences - The Malaysian Reserve
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 (PR Newswire) - Aktiellt
ADC Therapeutics (ADCT) Set to Announce Earnings on Thursday - MarketBeat
Cancer Antibody Drug Conjugates Market, Drugs Approval & Clinical Trials Report 2024 - GlobeNewswire Inc.
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Malaysian Reserve
Institutional investors own a significant stake of 32% in ADC Therapeutics SA (NYSE:ADCT) - Yahoo Finance
Global Antibody-Drug Conjugate Market Set for a ~USD 26 Billion Surge by 2030 | DelveInsight - The Malaysian Reserve
Antibody-Drug Conjugates Market to Grow at 28.4% CAGR from 2024 to 2029 - PR Newswire UK
The Manufacturers Life Insurance Company Purchases Shares of 26,938 ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA (NYSE:ADCT) Sees Large Growth in Short Interest - MarketBeat
Adc Therapeutics SA’s Shares Reel: -23.19% Quarterly Revenue Decline Amid 297.81M Market Cap - The InvestChronicle
Adc Therapeutics SA (ADCT) rating initates by Cantor Fitzgerald - Knox Daily
ADC Therapeutics SA's (NYSE:ADCT) institutional investors lost 10% over the past week but have profited from longer-term gains - Simply Wall St
Antibody Drug Conjugates Industry Report (2024-2032) - GlobeNewswire
Antibody Drug Conjugates Industry Report (2024-2032) Featuring Profiles the Top 13 PlayersADC Therapeutics, Astellas Pharma, AstraZeneca, Celldex Therapeutics, Roche & More - 24matins.uk
ADC Therapeutics : Subgroup analyses include patients with double- / triple-hit, advanced stage or transformed DLBCL, DLBCL refractory to first-line therapy, and patients older than 65 (Form 6-K) - Marketscreener.com
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):